Cumberland Pharmaceuticals Inc.
CPIX
$4.76
$0.235.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -2.60% | -8.55% | -9.09% | -5.02% | -7.79% |
| Total Other Revenue | -34.76% | 53.33% | 53.33% | 53.33% | 53.33% |
| Total Revenue | -4.26% | -6.45% | -7.05% | -3.08% | -5.85% |
| Cost of Revenue | 8.56% | -14.58% | -13.91% | -21.64% | -33.47% |
| Gross Profit | -6.58% | -4.64% | -5.46% | 1.66% | 1.80% |
| SG&A Expenses | -3.28% | 3.62% | 6.79% | 8.05% | 8.43% |
| Depreciation & Amortization | -0.22% | 11.50% | 5.73% | -1.38% | -6.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.20% | -1.70% | 1.47% | -1.37% | -4.09% |
| Operating Income | -3.57% | -31.36% | -86.44% | -10.16% | -8.87% |
| Income Before Tax | -2.88% | -345.72% | -479.65% | -108.54% | -12.61% |
| Income Tax Expenses | -149.89% | -14.08% | -20.61% | -27.14% | -33.67% |
| Earnings from Continuing Operations | -1.78% | -335.79% | -461.04% | -106.25% | -12.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -170.23% | -141.88% | -108.35% | -114.91% | -35.59% |
| Net Income | -3.19% | -348.15% | -481.30% | -110.83% | -12.73% |
| EBIT | -3.57% | -31.36% | -86.44% | -10.16% | -8.87% |
| EBITDA | -20.00% | -93.63% | -746.49% | -69.29% | -238.32% |
| EPS Basic | -3.90% | -355.21% | -492.48% | -116.35% | -15.93% |
| Normalized Basic EPS | -112.21% | -194.40% | -344.70% | -23.28% | 45.56% |
| EPS Diluted | -4.79% | -343.99% | -463.46% | -112.30% | -16.15% |
| Normalized Diluted EPS | -111.31% | -192.89% | -341.06% | -23.36% | 45.33% |
| Average Basic Shares Outstanding | -1.67% | -1.74% | -1.69% | -1.72% | -1.83% |
| Average Diluted Shares Outstanding | -2.33% | -2.40% | -2.35% | -1.83% | -1.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |